)
)
)
Leucid Bio
Leucid Bio is a privately held, biotechnology company developing novel, lateral CAR-Ts for the treatment of refractory cancers. The Company's lead candidate is LEU011 – an autologous, lateral CAR-T targeting NKG2D stress ligands currently in Phase I dose-escalation for the treatment of solid tumours.
Address
LondonEngland
United Kingdom
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)